Principal Technologies (FRA:JO7) Beta: N/A (As of Jul. 03, 2026)


FRA:JO7 Principal Technologies Inc FRA:JO7
1 GF Score
Price €0.20
GF Value €0.02
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Principal Technologies Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-03), Principal Technologies's Beta is Not available.

Principal Technologies  (FRA:JO7) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Principal Technologies Beta Related Terms

Principal Technologies Beta Historical Data

* Premium members only.

The historical data trend for Principal Technologies's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Principal Technologies Beta Chart

Principal Technologies Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Principal Technologies Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:JO7
1GF Score
Principal Technologies Inc FRA:JO7
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Principal Technologies Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Principal Technologies (FRA:JO7) Overvalued in 2026?

Based on GuruFocus' analysis, Principal Technologies stock appears to be overvalued. The current stock price of €0.20 is trading 875% above its estimated GF Value™ of €0.02. GuruFocus considers Principal Technologies to be Significantly Overvalued.

Key valuation signals for FRA:JO7:

  • Beta: N/A
  • GF Value™: €0.02 vs. price of €0.20 (875% above fair value)
  • GF Score™: 1/100 with 7 warning signs

No single metric tells the full story. See the FRA:JO7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Principal Technologies Business Description

Other Exchanges PTEC:Canada
Address 700 West Georgia Street, Suite 2500, Vancouver, BC, CAN, V7Y 1B3
Principal Technologies Inc is in the research and development stage of building a portfolio of medical technology assets with a focus on distribution potential and intellectual property capable of enhancing medical treatment, cost efficiency, and optimization of the patient pathway. The company focuses on acquiring medical technology research and development assets or developing them jointly with industry leaders. Its current revenue-generating activities are attributable to E&E CRO Consulting GmbH, which provides clinical research advisory services. The company operates in one reportable operational segment, consisting of project management of clinical studies and research related to medical device technologies.
1GF Score

Get the complete analysis for FRA:JO7

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.02
GF Value